blinatumomab: Clinical Trials

102 trials of blinatumomab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 recruiting, 21 completed, 17 active not recruiting, 13 not yet recruiting. 102 Phase 2, 19 Phase 1, 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2102Recruiting 34, Completed 21, Active not recruiting 17, Not yet recruiting 13, Terminated 8, Unknown 6, Withdrawn 3
Phase 119Active not recruiting 7, Recruiting 6, Completed 3, Not yet recruiting 2, Withdrawn 1
Phase 310Recruiting 6, Not yet recruiting 2, Active not recruiting 1, Completed 1

Follow blinatumomab: new trials by email Literature Review of blinatumomab trials Research Report on blinatumomab

Trials (filtered) newest first · largest first

All 102 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-01-272026-10-07
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult
Phase 1 / Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center262026-12-012026-11-09
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center302026-11-302026-11-02
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingSWOG Cancer Research Network902026-10-142026-10-13
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China222026-10-122026-09-25
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
Blinatumomab, background treatment - Primary Sjögren's Syndrome (pSS)
Phase 2Not yet recruitingBeijing Tongren Hospital122026-09-252026-10-01
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals502026-07-052026-11-12
Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial
Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China322026-06-122026-06-11
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3402026-05-182026-11-10
A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
BCL-2 indibitor, Azacitidine (AZA), Blinatumomab - Newly Diagnosed Mixed Phenotype Acute Leukemia
Phase 2Not yet recruitingThe First Affiliated Hospital of Soochow University522026-05-012026-05-07
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Blinatumomab - Phase 2 Study, Blinatumomab
Phase 2Active not recruitingM.D. Anderson Cancer Center402026-04-212026-11-12
ALL Backbone in AYAs
Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia
Phase 2RecruitingDana-Farber Cancer Institute672026-04-032026-08-17
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
Capivasertib, Venetoclax, Rituximab - Leukemia, Lymphoma
Phase 1 / Phase 2RecruitingUniversity of Chicago1042026-03-172026-03-04
A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center32026-01-302026-08-18
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Subcutaneous Blinatumomab - CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Phase 2RecruitingWest Virginia University782026-01-152026-04-13
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant
Phase 2 / Phase 3RecruitingBambino Gesù Hospital and Research Institute10002026-01-072026-10-20
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingAmgen1042025-12-082026-10-05
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
Blinatumomab plus Reduced-dose Chemotherapy - Acute Lymphoid Leukemia (ALL)
Phase 2Not yet recruitingXianmin Song, MD452025-09-012025-08-06
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Inebilizumab, Blinatumomab - Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Phase 2RecruitingAmgen2202025-07-162026-10-05
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)1532025-06-052026-11-18

Showing 20 of 102. Sign in to see all of them.

Conditions studied

Precursor Cell Lymphoblastic Leukemia-Lymphoma (47)  ·  Burkitt Lymphoma (31)  ·  Neoplasm, Residual (12)  ·  Leukemia (10)  ·  Recurrence (10)  ·  Leukemia, Biphenotypic, Acute (5)  ·  Lymphatic Diseases (5)  ·  Lymphoproliferative Disorders (5)  ·  Leukemia, Lymphoid (4)  ·  Lymphoma (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Immunoproliferative Disorders (3)  ·  Blast Crisis (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)

Sponsors

M.D. Anderson Cancer Center (15)  ·  Amgen (9)  ·  Amgen Research (Munich) GmbH (6)  ·  The First Affiliated Hospital of Soochow University (6)  ·  Institute of Hematology & Blood Diseases Hospital, China (5)  ·  National Cancer Institute (NCI) (5)  ·  St. Jude Children's Research Hospital (5)  ·  Goethe University (4)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Chen Suning (2)  ·  First Affiliated Hospital of Zhejiang University (2)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Sichuan University (2)  ·  Bambino Gesù Hospital and Research Institute (1)

Countries

United States (50)  ·  China (21)  ·  Germany (16)  ·  France (15)  ·  Italy (13)  ·  Canada (9)  ·  Spain (9)  ·  Australia (8)  ·  Belgium (7)  ·  Netherlands (6)  ·  United Kingdom (6)  ·  Austria (5)  ·  Puerto Rico (5)  ·  Israel (4)  ·  Japan (4)

Top investigators

Elias Jabbour (5)  ·  Elias Jabbour, MD (4)  ·  Nicola Goekbuget, MD (4)  ·  Brandon Triplett, MD (2)  ·  Max Topp, MD (2)  ·  Suning Chen (2)  ·  Xiaofan Zhu, MD (2)  ·  A.W. Rijneveld, Dr. (1)  ·  Alessandro Rambaldi (1)  ·  Anjali S Advani (1)  ·  Arend von Stackelberg, MD (1)

Results publications

PMID 41671463, PMID 35622074, PMID 27209293, PMID 22592608, PMID 25192414, PMID 25385737, PMID 25524800, PMID 26755709, PMID 27873237, PMID 27998223, PMID 28533941, PMID 28859185, PMID 28922466, PMID 29352703, PMID 29358182, PMID 30254079, PMID 31648325, PMID 32546071, PMID 32619115, PMID 33085860, PMID 33191168, PMID 34914826, PMID 35503708, PMID 35713551, PMID 35941212, PMID 36279879, PMID 36322825, PMID 36402146, PMID 37131217, PMID 37141547, PMID 37187201, PMID 38127722, PMID 38135369, PMID 38551807, PMID 39028925, PMID 39218935, PMID 39984805, PMID 40009490, PMID 40369607, PMID 41026957, PMID 41592282, PMID 41979896, PMID 42126414, PMID 42154791

NIH funding

2016 (3), 2025 (3), U10CA180886 (3), 2017 (2), U10CA180888 (2), 2015 (1), 2023 (1), P30CA093373 (1), U10CA180821 (1)